Ironwood Pharmaceuticals Stock (NASDAQ: IRWD)

Ironwood Pharmaceuticals

Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.

Marion,-,Circa,October,2021:,General,Motors,Logo,And,Signage

News

Downgrades

Pre-Market Outlook

Analyst Ratings

Trading Ideas

IRWD

MBLY

RLYB

This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

FDA’s Class II Risk

Biotech

Health Care

Movers

General

Ironwood must run a new Phase 3 trial after FDA talks, delaying its SBS drug approval despite strong results from prior studies.

Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug

Oil Prices

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

THTX

USAR

Longevity Health Holdings, Inc. - Common Stock

XAGE

Crude Oil Moves Lower; M&amp;T Bank Earnings Miss Views

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals Inc

Press Releases

Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference

Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future

Millrose Properties Set to Join S&P SmallCap 600

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance

Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

SPGI

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

Fate Therapeutics

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Inhibrx Biosciences

INmune Bio

Korro Bio

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nanobiotix

Nkarta

Puma Biotechnology

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Comments

Ironwood Pharmaceuticals

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell